CAS: 5034-06-0; Trimethyloxosulphonium Chloride

相似化合物

25596-24-1 1774-47-6 67-68-5

上下游产品

CAS号1774-47-6 三甲基碘化亚砜 | CAS号35155-66-9 3-chloro-2-meth... | CAS号70775-39-2 2-(4-chloro-phe... | CAS号1142-20-7 |N|-苄氧羰基-L-丙氨酸 | CAS号676486-18-3 dimethylsulfoxo... | CAS号185-72-8 1,6-二氧杂螺[2.5]辛烷 | CAS号74078-14-1 2-Hydroxyethyl-... | CAS号83868-59-1 5,5,7,7-tetrame...

三甲基碘化亚砜置于苄基三丁基氯化铵体系中,用 二氯甲烷,水 作为反应溶剂,化学反应 24.0H,以84%的收率获得产物三甲基氯化亚砜
参考文献:结合多均相和开环聚合的新型三晶三嵌段三元共聚物.合成和热性能
标题:结合多均相和开环聚合的新型三晶三嵌段三元共聚物.合成和热性能
摘要:新tricrystalline三嵌段三元共聚物,聚乙烯-嵌段-聚(ε-己内酯)-嵌段-聚(大号丙交酯)(pe-B-Pcl-B-Plla),通过的rop合成ε己内酯(cl)和大号-线性ω-羟基聚乙烯(pe-Oh)大分子引发剂合成丙交酯(lla).线性pe-Oh大分子引发剂是通过c1甲基methyl基亚砜(多同系物)聚合制备的.2-乙基己酸锡(II)在85oc的甲苯中一锅聚合中用作cl和lla的顺序rop的催化剂(pe-Oh大分子引发剂可在80oc的甲苯中溶解).1个1 H NMR光谱通过每个嵌段的特征性质子峰的出现证实了pe B B Pcl B Plla三嵌段三元共聚物的形成.gpc痕迹表明,从pe-Oh大分子引发剂到pe-B-Pcl的数均分子量增加,而pe-B-Pcl-B-Plla证实了成功的合成.dsc和xrd光谱证明存在三个结晶块.©2019作者.高分子科学杂志a部分:高分子化学,由wiley
DOI:10.1002/pola.29492

专利信息

专利号:US-5476915-A
优先权日:1994-06-29
标题:Method for controlled synthesis of polymers
发明人：SHEA KENNETH J; WALKER JAMES R; ZHU HIUDE
权利人:UNIV CALIFORNIA
摘要:Living polymer synthesis methods for the synthesis of oligomeric and high molecular weight polymers with low polydispersity are disclosed. The disclosed methods are based on the discovery that the reaction of a ylid with an organoborane at a high ylid:borane ratio and high temperature provides for the synthesis of high molecular weight polymers with low polydispersity.

专利号:US-2024336586-A1
优先权日:2021-07-29
标题:Methods for synthesis of racemic, scalemic, and chiral alpha-tocotrienol quinone
发明人：GIANNOUSIS PETER; MOLLARD PAUL; GOUDEDRANCHE SEBASTIEN; KARASAWA TOMOYA
权利人:PTC THERAPEUTICS INC
摘要:The application discloses methods useful for the synthesis of racemic, scalemic, and chiral alpha-tocotrienol quinone, including synthetic intermediates and methods for making said synthetic intermediates.

专利号:US-2012053350-A1
优先权日:2009-04-30
标题 :Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
发明人：MANGION IAN; HUFFMAN MARK A; RUCK REBECCA T; LYNCH JOSEPH; CHUNG JOHN Y L; MARCUNE BENJAMIN
权利人:MANGION IAN; HUFFMAN MARK A; RUCK REBECCA T; LYNCH JOSEPH; CHUNG JOHN Y L; MARCUNE BENJAMIN
摘要:A process for the preparation of alkyl esters of N-protected oxo-azacycloalkylcarboxylic acids of Formula III: comprises contacting a ketosulfoxonium ylide of Formula II: with an iridium catalyst to obtain Compound III, wherein P G1 is an amine protective group; k is 0, 1, or 2; and R U , R 1 , R 2 , and R 3 are defined herein. An embodiment of the process further com rises contacting a compound of Formula I: with a sulfoxonium halide of formula (R U ) 3 S(O)Z, wherein Z is halide, in the presence of a strong base to obtain Compound II. Additional embodiments add a series of process steps leading to the synthesis of 7-oxo-1,6-diazabicyclo[3.2.1]octanes suitable for use as β-lactamase inhibitors.

专利号:US-9045462-B2
优先权日:2012-08-17
标 题 :Synthesis of an antiviral compound
发明人：EVANS JARED WAYNE; FUJIMORI SHINJI; HUYNH GRACE M; LIU QI; TERESK MARTIN GERALD
权利人:GILEAD SCIENCES INC
摘要:The present disclosure provides processes for the preparation of a compound of Formula I: n nwhich is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula.

专利号:US-8927741-B2
优先权日:2012-08-17
标 题 :Synthesis of an antiviral compound
发明人：WATKINS WILLIAM JOHN; LIU QI
权利人:GILEAD SCIENCES INC
摘要:The present disclosure provides a processes for the preparation of a compound of Formula I: n nwhich is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of Formula I.

专利号:US-11976077-B2
优先权日:2015-10-16
标 题 :Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof
发明人：PANGAN AILEEN L; TEIXEIRA HENRIQUE D; MOHAMED MOHAMED-ESLAM F; OTHMAN AHMED A; KLÃœNDER BEN; VOSS JEFFREY W; PADLEY ROBERT J; CAMP HEIDI S
权利人:ABBVIE INC
摘要:The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.